COVID-19: From pathogenesis models to the first drug trials.
Microb Biotechnol
; 13(5): 1289-1299, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-1352399
ABSTRACT
The number of people infected with SARS-CoV-2, and sadly dying from COVID-19, has exploded, and so the amount of literature on the novel coronavirus and the disease it causes has increased proportionately. The case numbers in some countries are beyond the epidemic peak, but the uncertainty about a second wave keeps politicians and societies under pressure. Appropriate decision-making and winning support from the population depends on precise scientific information rather than leaving the field to scaremongers of all proveniences. This mini-review is an update of earlier reports (Brüssow, Microb Biotechnol 2020a;13607; Brüssow, Microb Biotechnol 2020b; https//doi.org/10.1111/1751-7915.13592).
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Animals
/
Humans
Language:
English
Journal:
Microb Biotechnol
Year:
2020
Document Type:
Article
Affiliation country:
1751-7915.13611
Similar
MEDLINE
...
LILACS
LIS